DK0825865T3 - Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat - Google Patents

Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat

Info

Publication number
DK0825865T3
DK0825865T3 DK96919765T DK96919765T DK0825865T3 DK 0825865 T3 DK0825865 T3 DK 0825865T3 DK 96919765 T DK96919765 T DK 96919765T DK 96919765 T DK96919765 T DK 96919765T DK 0825865 T3 DK0825865 T3 DK 0825865T3
Authority
DK
Denmark
Prior art keywords
testosterone
administration
therapeutic system
transdermal therapeutic
derivative
Prior art date
Application number
DK96919765T
Other languages
English (en)
Inventor
Wilfried Fischer
Daniel Bracher
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of DK0825865T3 publication Critical patent/DK0825865T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nanotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK96919765T 1995-05-10 1996-05-10 Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat DK0825865T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19517145A DE19517145C2 (de) 1995-05-10 1995-05-10 Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
PCT/EP1996/002013 WO1996035427A1 (de) 1995-05-10 1996-05-10 Transdermales therapeutisches system (tts) zur verabreichung von testosteron

Publications (1)

Publication Number Publication Date
DK0825865T3 true DK0825865T3 (da) 2002-02-18

Family

ID=7761562

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919765T DK0825865T3 (da) 1995-05-10 1996-05-10 Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat

Country Status (17)

Country Link
EP (1) EP0825865B1 (da)
JP (1) JPH11504643A (da)
CN (1) CN1183723A (da)
AT (1) ATE208200T1 (da)
AU (1) AU702710B2 (da)
BR (1) BR9608255A (da)
CA (1) CA2220358A1 (da)
CZ (1) CZ287678B6 (da)
DE (2) DE19517145C2 (da)
DK (1) DK0825865T3 (da)
HU (1) HUP9801130A3 (da)
NO (1) NO975140L (da)
NZ (1) NZ308516A (da)
PL (1) PL323145A1 (da)
SK (1) SK149797A3 (da)
WO (1) WO1996035427A1 (da)
ZA (1) ZA963743B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
EP0909167B1 (en) * 1996-07-03 2002-10-30 Alza Corporation Drug delivery devices and process of manufacture
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
DE19646050A1 (de) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermales System mit einem speziellen Süßstoff zur Erhöhung der transdermalen Bioverfügbarkeit
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE602005020393D1 (de) 2004-06-01 2010-05-20 Hisamitsu Pharmaceutical Co Adhäsive Pflaster
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
CN101480399B (zh) * 2008-09-25 2011-10-05 宋博 睾酮在制备治疗弱精子症的药物中的应用
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
ATE184473T1 (de) * 1992-06-11 1999-10-15 Theratech Inc Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
DE59409873D1 (de) * 1993-04-20 2001-10-25 Hexal Ag Wirkstoffpflaster
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women

Also Published As

Publication number Publication date
NO975140D0 (no) 1997-11-07
PL323145A1 (en) 1998-03-16
CZ287678B6 (en) 2001-01-17
DE19517145C2 (de) 2000-02-24
DE59608150D1 (de) 2001-12-13
HUP9801130A2 (hu) 1998-08-28
CN1183723A (zh) 1998-06-03
CZ351297A3 (cs) 1998-03-18
HUP9801130A3 (en) 2001-03-28
CA2220358A1 (en) 1996-11-14
AU702710B2 (en) 1999-03-04
NO975140L (no) 1997-11-10
DE19517145C1 (de) 1996-11-28
WO1996035427A1 (de) 1996-11-14
NZ308516A (en) 1999-05-28
EP0825865B1 (de) 2001-11-07
ZA963743B (en) 1996-11-18
JPH11504643A (ja) 1999-04-27
AU5805096A (en) 1996-11-29
EP0825865A1 (de) 1998-03-04
SK149797A3 (en) 1998-05-06
BR9608255A (pt) 1999-02-02
ATE208200T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
FI953533L (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
DE19680582D2 (de) Hormonpflaster
ITMI961152A0 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
NO992674L (no) Konturen til et transdermalt terapeutisk system
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
NO975140D0 (no) Transdermalt terapeutisk system (TTS) for administrasjon av testosteron
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
PT98416A (pt) Processo para a preparacao de um sistema matricial de silicone elastomerico autoadesivo destinado a administracao prolongada de piribedilo por via transcutanea
DE69626544D1 (de) Arzneistoffe
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
AU637861B2 (en) Improved system for the transdermal application of pharmacologically active compounds at controlled ph
ATE211383T1 (de) Topische aciclovir-zubereitung
DK1001942T3 (da) Polyhydroxybutylpyraziner, deres fremstilling samt medikamenter indeholdende disse forbindelser
CY1105463T1 (el) Ελεγχομενη χορηγηση αντικαταθλιπτικων
ES2170377T3 (es) Composicion que contiene quitosana.
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
WO2001003678A3 (de) Transdermales therapeutisches system zur anwendung von tolterodin
EP0729950A4 (en) ANTI-HIV MEDICINAL PRODUCTS
ZA966083B (en) Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.
AU4015097A (en) Transdermal therapeutic system having an active compound combination comprising oestriol
GR1001412B (el) Συν?έσεις χρήσιμες δια την ?εραπευτική αγωγή της ξηρότητος του κόλπου.
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.